MKI67 and breast cancer: Second, the use of genomic markers of proliferation differs from the more recent routine use of KI67 (71), although genomic signatures of proliferation are the strongest factor for prognostic stratification in most predictive genomic tests in early luminal BC (60, 72) and also comprise a key prognostic marker in non-luminal subtypes (73, 74).